Alnylam Generates 3.36x Return on Capital with 19.66% ROIC
ALNY•Alnylam Pharmaceuticals reported a ROIC of 19.66% against a WACC of 5.85%, generating a ROIC-to-WACC ratio of 3.36. Peers such as BioMarin reported a 3.92% ROIC versus a 5.19% WACC, and Ionis, Sarepta and Agios posted negative ROICs.
1. Strong Financial Efficiency
Alnylam Pharmaceuticals achieved a 19.66% return on invested capital compared with a 5.85% weighted average cost of capital, yielding a ROIC-to-WACC ratio of 3.36. This indicates the company generates more than three times the return required by its investors, highlighting efficient use of capital in its RNAi therapeutics business.
2. Peers Exhibit Weaker Returns
BioMarin reported a 3.92% ROIC against a 5.19% WACC, resulting in value destruction as returns fall below capital costs. Other biopharmaceutical peers including Ionis, Sarepta and Agios recorded negative ROICs, reflecting early-stage development investments and mounting shareholder dilution risks.
3. Implications for Shareholder Value
Alnylam’s superior capital returns position it for potential premium valuation relative to peers, as consistent value creation can support share price appreciation. Monitoring sustainability of high ROIC levels and potential pipeline milestones will be critical for investors assessing future growth and profitability.
